المؤلفون: de Rosa, C., Morgillo, F., Amato, L., Tuccillo, C., Ciardiello, F., Della Corte, C.M.

المصدر: ESMO Open ; volume 9, page 102777 ; ISSN 2059-7029

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1016/j.esmoop.2024.102777Test
https://api.elsevier.com/content/article/PII:S2059702924005453?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2059702924005453?httpAccept=text/plainTest

المؤلفون: Gagliardi, F., Nardone, V., Grassi, R., Belfiore, M., Roccatagliata, P., Buono, M., Cimmino, G., Della Corte, C.M., Morgillo, F., Ciardiello, F., Reginelli, A., Cappabianca, S.

المصدر: ESMO Open ; volume 9, page 102737 ; ISSN 2059-7029

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1016/j.esmoop.2024.102737Test
https://api.elsevier.com/content/article/PII:S2059702924005052?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2059702924005052?httpAccept=text/plainTest

المؤلفون: Tabernero, J., Taieb, J., Fakih, M., Prager, G.W., Van Cutsem, E., Ciardiello, F., Mayer, R.J., Amellal, N., Skanji, D., Calleja, E., Yoshino, T.

المساهمون: Servier Institute

المصدر: ESMO Open ; volume 9, issue 3, page 102945 ; ISSN 2059-7029

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1016/j.esmoop.2024.102945Test
https://api.elsevier.com/content/article/PII:S2059702924007130?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2059702924007130?httpAccept=text/plainTest

المؤلفون: Martini, G, Ciardiello, D, Famiglietti, V, Rossini, D, Antoniotti, C, Troiani, T, Napolitano, S, Esposito, L, Latiano, T P, Maiello, E, Del Re, M, Lonardi, S, Aprile, G, Santini, D, Masi, G, Avallone, A, Normanno, N, Pietrantonio, F, Pinto, C, Ciardiello, F, Cremolini, C, Martinelli, E

المساهمون: Martini, G, Ciardiello, D, Famiglietti, V, Rossini, D, Antoniotti, C, Troiani, T, Napolitano, S, Esposito, L, Latiano, T P, Maiello, E, Del Re, M, Lonardi, S, Aprile, G, Santini, D, Masi, G, Avallone, A, Normanno, N, Pietrantonio, F, Pinto, C, Ciardiello, F, Cremolini, C, Martinelli, E

مصطلحات موضوعية: cetuximab, immunotherapy, metastatic colorectal cancer, rechallenge

الوصف: The rechallenge strategy is based on the concept that a subset of patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) could still benefit of epidermal growth factor receptor (EGFR) inhibition, after progression to an anti-EGFR based-therapy. We performed a pooled analysis of two-phase II prospective trials to determine the role of rechallenge in third-line mCRC patients with RAS/BRAF WT baseline circulating tumor DNA (ctDNA). Individual data of 33 and 13 patients from CAVE and CRICKET trials that received as third-line therapy cetuximab rechallenge were collected. Overall survival (OS), Progression-free survival (PFS), Overall response rate (ORR), Stable disease (SD) >6months were calculated. Adverse events were reported. For the whole 46 patient population, median PFS (mPFS) was 3.9months (95% Confidence Interval, CI 3.0-4.9) with median OS (mOS) of 16.9months (95% CI 11.7-22.1). For CRICKET patients, mPFS was 3.9months (95% CI 1.7-6.2); mOS was 13.1months (95% CI 7.3-18.9) with OS rates at 12, 18, and 24 months of 62%, 23%, and 0%, respectively. For CAVE patients, mPFS was 4.1months (95% CI 3.0-5.2); mOS was 18.6months (95% CI 11.7-25.4) with OS rates at 12, 18, 24 months of 61%, 52%, 21%, respectively. Skin rash was more frequently reported in CAVE trial (87.9% vs. 30.8%; p=0.001), whereas a increased incidence of hematological toxicities was observed in CRICKET trial (53.8%% vs. 12.1%; p=0.003). Third-line cetuximab rechallenge in combination with either irinotecan or avelumab in RAS/BRAF WT ctDNA mCRC patients represents a promising therapy.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36880426; info:eu-repo/semantics/altIdentifier/wos/WOS:000944145900001; volume:12; issue:8; numberofpages:9; journal:CANCER MEDICINE; https://hdl.handle.net/11568/1169589Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85150336357

الإتاحة: https://doi.org/10.1002/cam4.5699Test
https://hdl.handle.net/11568/1169589Test

المؤلفون: Troiani, T, Vecchione, L, Martinelli, E, Capasso, A, Costantino, S, Ciuffreda, LP, Morgillo, F, Vitagliano, D, D'Aiuto, E, De Palma, R, Tejpar, S, Van Cutsem, E, De Lorenzi, M, Caraglia, M, Berrino, L, Ciardiello, F

المصدر: British journal of cancer. 106(10):1648-1659

مصطلحات موضوعية: Medicin och hälsovetenskap

الوصول الحر: http://kipublications.ki.se/Default.aspx?queryparsed=id:124566821Test

المؤلفون: Schmoll, HJ, Van Cutsem, E, Stein, A, Valentini, V, Glimelius, B, Haustermans, K, Nordlinger, B, van de Velde, CJ, Balmana, J, Regula, J, Nagtegaal, ID, Beets-Tan, RG, Arnold, D, Ciardiello, F, Hoff, P, Kerr, D, Kohne, CH, Labianca, R, Price, T, Scheithauer, W, Sobrero, A, Tabernero, J, Aderka, D, Barroso, S, Bodoky, G, Douillard, JY, El Ghazaly, H, Gallardo, J, Garin, A, Glynne-Jones, R, Jordan, K, Meshcheryakov, A, Papamichail, D, Pfeiffer, P, Souglakos, I, Turhal, S, Cervantes, A

المصدر: Annals of oncology : official journal of the European Society for Medical Oncology. 23(10):2479-2516

مصطلحات موضوعية: Medicin och hälsovetenskap

الوصول الحر: http://kipublications.ki.se/Default.aspx?queryparsed=id:125364671Test

المؤلفون: Yoshino, T. (Takayuki), Di-Bartolomeo, M. (Maria), Raghav, K. (Kanwal), Masuishi, T. (Toshiki), Loupakis, F. (Fotios), Kawakami, H. (Hisato), Yamaguchi, K. (Kensei), Nishina, T. (Tomohiro), Wainberg, Z. (Zev), Elez, E. (Elena), Rodríguez-Rodríguez, J. (Javier), Fakih, M. (Marwan), Ciardiello, F. (Fortunato), Saxena, F. (Kapil), Kobayashi, K. (Kojiro), Bako, E. (Emarjola), Okuda, Y. (Yasuyuki), Meinhardt, G. (Gerold), Grothey, A. (Axel), Siena, S. (Salvatore)

مصطلحات موضوعية: Área de Medicina Clínica y Epidemiología, Trastuzumab deruxtecan (T-DXd), Metastatic colorectal cancer (mCRC), Objective response rate (ORR)

الوصف: DESTINY-CRC01 (NCT03384940) was a multicenter, open-label, phase 2 trial assessing the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing metastatic colorectal cancer (mCRC) that progressed after >= 2 prior regimens; results of the primary analysis are published. Patients received T-DXd 6.4mg/kg every 3 weeks and were assigned to either: cohort A (HER2-positive, immunohistochemistry [IHC] 3+ or IHC 2+/in situ hybridization [ISH]+), cohort B (IHC 2+/ISH-), or cohort C (IHC 1+). Primary endpoint was objective response rate (ORR) by independent central review in cohort A. Secondary endpoints included ORR (cohorts B and C), duration of response, disease control rate, progression-free survival, overall survival, pharmacokinetics, and safety of T-DXd. 86 patients were enrolled (53 in cohort A, 15 in cohort B, and 18 in cohort C). Results of the primary analysis are published, reporting an ORR of 45.3% in cohort A. Here, we report the final results. No responses occurred in cohorts B or C. Median progression-free survival, overall survival, and duration of response were 6.9, 15.5, and 7.0 months, respectively. Overall serum exposure (cycle 1) of T-DXd, total anti-HER2 antibody, and DXd were similar regardless of HER2 status. Most common grade >= 3 treatment-emergent adverse events were decreased neutrophil count and anemia. Adjudicated drug-related interstitial lung disease/pneumonitis occurred in 8 patients (9.3%). These findings support the continued exploration of T-DXd in HER2-positive mCRC.

وصف الملف: application/pdf

العلاقة: https://pubmed.ncbi.nlm.nih.gov/37286557Test/; https://hdl.handle.net/10171/67553Test

الإتاحة: https://hdl.handle.net/10171/67553Test

المؤلفون: Ciardiello, F., Genovese, A.

الوصف: The Technique for Order of Preference by Similarity to Ideal Solution (TOPSIS) and Simple Additive Weighting (SAW) are among the most employed approaches for aggregating performances in Multi-Criteria Decision-Making (MCDM). TOPSIS and SAW are two MCDM methods based on the value function approach and are often used in combination with other MCDM methods in order to produce rankings of alternatives. In this paper, first, we analyse some common features of these two MCDM methods with a specific reference to the additive properties of the value function and to the sensitivity of the value function to trade-off weights. Based on such methodological insights, an experimental comparison of the results provided by these two aggregation methods across a computational test is performed. Specifically, similarities in rankings of alternatives produced by TOPSIS and SAW are evaluated under three different Minkowski distances (namely, the Euclidean, Manhattan and Tchebichev ones). Similarities are measured trough a set of statistical indices. Results show that TOPSIS, when used in combination with a Manhattan distance, produces rankings which are extremely similar to the ones resulting from SAW. Similarities are also Experimental results confirm that rankings produced by TOPSIS methods are closer to SAW ones when similar formal properties are satisfied.

وصف الملف: text

العلاقة: https://eprints.whiterose.ac.uk/199927/1/s10479-023-05339-w.pdfTest; Ciardiello, F. orcid.org/0000-0002-6304-7979 and Genovese, A. (2023) A comparison between TOPSIS and SAW methods. Annals of Operations Research, 325. pp. 967-994. ISSN 0254-5330

الإتاحة: https://eprints.whiterose.ac.uk/199927Test/
https://eprints.whiterose.ac.uk/199927/1/s10479-023-05339-w.pdfTest

المؤلفون: de Rosa, C., Tuccillo, C., Amato, L., Ciardiello, F., Nardone, V., Morgillo, F., Della Corte, C.M.

المصدر: Immuno-Oncology and Technology ; volume 20, page 100627 ; ISSN 2590-0188

مصطلحات موضوعية: Oncology, Immunology and Allergy

الإتاحة: https://doi.org/10.1016/j.iotech.2023.100627Test
https://api.elsevier.com/content/article/PII:S2590018823002903?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2590018823002903?httpAccept=text/plainTest

المؤلفون: Martini, G., Belli, V., Napolitano, S., Ciaramella, V., Ciardiello, D., Belli, A., Izzo, F., Avallone, A., Selvaggi, F., Menegon Tasselli, F., Santaniello, W., Franco, R., Puig, I., Ramirez, L., Chicote, I., Mancuso, F., Caratu, G., Serres, X., Fasani, R., Jimenez, J., Ros, J., Baraibar, I., Mulet, N., Della Corte, C.M., Troiani, T., Vivancos, A., Dienstmann, R., Elez, E., Palmer, H.G., Tabernero, J., Martinelli, E., Ciardiello, F., Argilés, G.

المصدر: ESMO Open ; volume 8, issue 3, page 101198 ; ISSN 2059-7029

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1016/j.esmoop.2023.101198Test
https://api.elsevier.com/content/article/PII:S2059702923004209?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2059702923004209?httpAccept=text/plainTest